The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor

NCT03505164 · clinicaltrials.gov ↗

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Doxorubicin Adverse Reaction
Cardiomyopathies, Secondary
Breast Cancer

Sponsor

Rush University Medical Center